gutflix
GI learning, personalised

Summary

EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF 2,254 EMPIRICAL RESCUE THERAPIES ON THIRD AND SUBSEQUENT LINES

Samuel Jesús Martínez-Domínguez

UEG Week Copenhagen 2023 | Poster

Stomach & H. Pylori

October 15, 2023

A European registry study of 2,254 third-line and subsequent Helicobacter pylori rescue treatments found overall effectiveness of 73% by modified intention-to-treat analysis, with single-capsule bismuth quadruple therapy achieving the highest cure rate at 86%.

KEY POINTS

- Among 63 different empirical regimens used across third- to sixth-line treatments, single-capsule bismuth quadruple therapy (PPI-bismuth-tetracycline-metronidazole) was most commonly prescribed and achieved 86% effectiveness by modified intention-to-treat analysis.
- Only one regimen reached optimal eradication (≥90%): quadruple PPI-bismuth-tetracycline-metronidazole, and only when high-dose PPIs and 14-day duration were used.
- Doxycycline substitution for tetracycline in classical bismuth quadruple therapies was associated with significantly lower eradication rates ($p<0.05$).
- The study included 1,624 third-line, 424 fourth-line, 150 fifth-line, and 56 sixth-line treatments from a prospective European registry spanning 32 countries.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/8f5b576e-743b-11ee-837b-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.